Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: pimecrolimus
BRAND NAME: Elidel
DRUG CLASS AND MECHANISM: Pimecrolimus is a chemical that is used to treat atopic dermatitis (eczema). Atopic dermatitis is a skin condition characterized by redness, itching, scaling, and inflammation of the skin. The cause of atopic dermatitis is not known; however, scientists believe that it may be due to activation of the immune system by various environmental or emotional triggers. Scientists do not know exactly how pimecrolimus reduces the manifestations of atopic dermatitis, but pimecrolimus reduces the action of T-cells and mast cells which are part of the immune system and contribute to responses of the immune system. Pimecrolimus prevents the activation of T-cells by blocking the effects of chemicals (cytokines) released by the body that stimulate T-cells. Pimecrolimus also reduces the ability of mast cells to release chemicals that promote inflammation. Pimecrolimus was approved by the FDA in December 2001.
GENERIC AVAILABLE: No
PREPARATIONS: Cream, 1%
STORAGE: Pimecrolimus should be stored at room temperature, 15-30 C (59-86 F).
PRESCRIBED FOR: Pimecrolimus is used for the short-term treatment of mild to moderate atopic dermatitis in individuals who are two years of age or older and who cannot use or have failed to respond to other therapies. Pimecrolimus should not be used by individuals with a weakened immune system.
DOSING: Patients should completely rub in a thin layer of pimecrolimus to the affected areas twice daily. An improvement in symptoms can be seen within 8-15 days, and patients should contact their physician if there is no response after six weeks of use.
DRUG INTERACTIONS: Interactions between pimecrolimus and other drugs have not been studied. Since very little pimecrolimus is absorbed from the skin, drug interactions are not expected. However, since some pimecrolimus is absorbed, caution should be exercised when pimecrolimus is used by individuals also taking drugs (for exmaple, ketoconazole [Nizoral, Extina, Xolegel, Kuric], itraconazole [Sporanox], erythromycin, fluconazole [Diflucan], calcium channel blockers [CCBs], cimetidine [Tagamet]) that inhibit the liver enzymes that eliminate pimecrolimus and could increase the levels of pimecrolimus and promote its toxicity.
PREGNANCY: There are no adequate studies that evaluate the use of pimecrolimus during pregnancy.
NURSING MOTHERS: Use of pimecrolimus by nursing mothers has not been evaluated, and it is not known if pimecrolimus is excreted in breast milk. Nursing mothers should decide whether to stop nursing or use alternative treatments.
SIDE EFFECTS: The most common side effects of pimecrolimus are reactions at the site of application. These include burning, itching and redness. Other side effects that may occur include sore throat, stuffy nose, headache, cough, respiratory tract and viral infections. Skin cancer and lymphoma have rarely occurred during treatment with pimecrolimus. Therefore, pimecrolimus should not be used for long-term treatment and should only be applied to affected areas.
Reference: FDA Prescribing Information
Last Editorial Review: 6/14/2012
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index